Hematologic Oncology | Specialty

Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015

Immunotherapy-Related Adverse Events

June 24th 2015

Responses With Immunotherapy Versus Chemotherapy

June 24th 2015

Immunotherapy in Hematologic Malignancies

June 24th 2015

Cheson on Obinutuzumab's Potential for Patients With Rituximab-Refractory iNHL

June 24th 2015

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Expanded Idelalisib Indication in CLL on Horizon After Positive Phase III Combo Trial With Ofatumumab

June 24th 2015

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

June 23rd 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

June 20th 2015

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Lenalidomide Highly Effective in Early Phase CNS Lymphoma Study

June 20th 2015

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

Ibrutinib, Ublituximab, TGR-1202 Triplet Active in Relapsed B-Cell Malignancies

June 19th 2015

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

PI3Kδ and JAK1 Inhibitors Show Promise in Advanced Hodgkin Lymphoma

June 19th 2015

The PI3Kδ inhibitor INCB040093 alone or in combination with the JAK1 inhibitor INCB039110 showed early promise in relapsed/refractory classical Hodgkin lymphoma.

Nivolumab Elicits Durable Responses in Lymphoma

June 19th 2015

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

Rituximab, Thiotepa, and Chemo Combo Improves Outcomes in Primary CNS Lymphoma

June 18th 2015

The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma.

SYK Inhibitor TAK-659 Shows Promising Results in Lymphoid Malignancies

June 18th 2015

TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.

2015 EHA Congress Highlights

June 18th 2015

Interim FDG-PET Scans Enable Response-Adapted Therapy in Hodgkin Lymphoma

June 18th 2015

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

IDH Inhibition Shows Promise in Two Early Phase AML Studies

June 15th 2015

The IDH1 inhibitor AG-120 and the IDH2 inhibitor AG-221 have demonstrated promising outcomes in patients with hematologic malignancies, including those with acute myeloid leukemia in two separate phase I clinical trials.

Inotuzumab Ozogamicin Shows High MRD-negative CR Rate in ALL

June 14th 2015

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

June 11th 2015

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).